You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 4,320,115


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 4,320,115
Title: Rabies virus vaccine
Abstract:A novel rabies virus strain No. 675 deposited in the Czechoslovak National Collection of Type Cultures of the Institute of Hygiene and Epidemiology in Prague under number CNCTO AO 4/77, novel living or inactivated cell culture vaccines derived therefrom, a process for the isolation of the virus strain as well as a process for the preparation of the said vaccines and novel method of immunizing warm-blooded animals against rabies.
Inventor(s): Bijlenga; Gosse (St. Didier au Mont d\'Or, FR)
Assignee: Gist-Brocades N.V. (Delft, NL)
Application Number:05/872,056
Patent Claims:1. A live or inactivated rabies virus vaccine wherein the virus vaccine is derived from a rabies strain novel species No. 675 deposited with Czechoslovak National Collection of Type Culture of the Institute of Hygiene and Epidemiology in Prague and is in an injectable pharmaceutically acceptable liquid, the amount of vaccine being sufficient to combat rabies infections.

2. A vaccine of claim 1 further containing at least one member of the group consisting of stabilizers, preservatives, buffering salts and adjuvants.

3. A live rabies virus vaccine for oral administration wherein the virus vaccine is derived from a rabies virus strain novel species No. 675 deposited with Czechoslovak National Collection of Type Culture of the Institute of Hygiene and Epidemiology in Prague and is incorporated in baits, the amount of vaccine being sufficient to combat rabies infections.

4. A vaccine of claim 3 wherein the bait is a meat ball.

5. Baits containing a live rabies virus vaccine wherein the virus vaccine is derived from a rabies virus strain novel species No. 675 deposited with the Czechoslovak National Collection of Type Culture of the Institute of Hygiene and Epidemiology in Prague, the amount of vaccine being sufficient to combat rabies infections.

6. A process for the preparation of live or inactivated rabies virus vaccines of claim 1 derived from the rabies virus strain novel species no. 675 comprising preparing vaccine by growing the rabies virus in cell systems which are sufficiently susceptible to rabies infection of cells of avian origin or mammalian cells, freezing the cell suspension at temperature of at least -70.degree. C. and/or subjecting the cell suspension to ultrasonic vibration to disrupt the cells and release the virus, removing the cells and cell debris by filtration or centrifugation under sterile conditions and optionally inactivating the virus in the culture fluids.

7. The process of claim 6 wherein chicken embryo fibroblasts are infected with the rabies seed virus strain no. 675 having a multiplicity of infection of 0.02 to 1 pfu/cell, the infection period is at least one hour and adding a maintenance medium of pH 8.0 to 8.2 after removal of unattached virus, incubating the virus infected cells at 32.degree.-39.degree. C. for 3-10 days, freezing the cells and medium to at least -70.degree. C. and filtering or centrifuging under sterile conditions the mixture and optionally inactivating the virus in the culture fluids.

8. A process of claim 7 wherein the maintenance medium is Basal medium Eagle (BME) in Earle's salt solution to which appropriate amounts of antibiotics and 0.2-0.5% of albumin are added.

9. A process of claim 6 wherein Baby Hamster Kidney 21 (21 passages) 13 S (13 passages of suspension culture) cells, grown in suspension in a spinner flask in a BHK-21 medium for spinner culture to which small amounts of tryptose phosphate broth, inactivated calf serum and antibiotics, have been added to obtain a level of about 2.times.10.sup.6 cells/ml infected with rabies seed virus strain 675 in a multiplicity of infection between 0.01 to 1 under stirring, incubating the virus in suspension in a maintenance medium at a pH between 7.5 and 8.0 and at a temperature of 32.degree.-35.degree. C. for 4-6 days after infection, freezing the cells and medium at a temperature of at least -70.degree. C. and filtering or centrifuging the mixture under sterile conditions and optionally inactivating the virus in the culture fluids.

10. A method of vaccinating warm-blooded animals against rabies comprising administering to warm-blooded animals an antirabies effective amount of an attenuated liquid antirabies vaccine of claim 1.

11. The method of vaccinating warm-blooded animals against rabies as in claim 10 wherein the vaccine is administered orally.

12. The method of claim 11 wherein the vaccine is incorporated in a bait.

13. A method of protecting wild carnivores from rabies infection comprising orally administering to said carnivores an immunizing dose of the attenuated rabies vaccine strain no. 675 containing a temperature stabilizer, said vaccine being enclosed in a bite-permeable container and said container being surrounded by an acceptable meat bait for said carnivores.

14. The method of claim 13 wherein the wild carnivore is a fox.

15. Method of protecting of man and animals after exposure to rabies infections by the administration of the vaccines according to claim 1 in the form of booster shots to man and animals, which had been vaccinated already.

16. Method according to claim 15, characterized in that the live rabies vaccine is applied several days after exposure.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.